In Truth on the Market, we argued that a brain-injury blood test's 20-year road to patients shows why Congress must fix patent eligibility law.

Jeffrey Depp joins a Federalist Society panel with Alden Abbott, Jane Bambauer and Satya Marar on intellectual property, AI training and fair use.

In IPWatchdog, we argued that by taking Hikma v. Amarin, the Supreme Court chose a narrow drug-pricing fight over the patent questions that matter.

In Truth on the Market, we argued that Hikma v. Amarin reflects a fatal conceit: that courts and regulators can engineer cheaper drugs.

The following is a statement from Curt Levey, the Committee for Justice's president and one of the attorneys on the brief...

Copyright cases do not call for a free-ranging search for the best copyright policy, but rather depends solely on statutory interpretation.

The recent Texas state verdict that Title Source misappropriated proprietary data from former collaborator HouseCanary underscores the rise

Ashley Baker discusses the impact of two recent Supreme Court decisions that have produced a “sea change in intellectual property litigation

For trade secrets law, 2019 was a formative year for both public knowledge and litigation trends. Due to extensive media coverage of Huawei